A profitable company. Institutions are adding.
Facts from SEC filings, not a recommendation.
From CBIO's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Over 5 years, sales grew about 1.3% a year.
Move the sliders to your own view of CBIO. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).
What today's price needs: with a 10% margin and a 15x P/E, sales would have to grow about 96% a year for 5 years just to match today's price.
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
Price chart by TradingView.
From annual reports filed with the SEC. Not in this company's SEC data, so not scored: share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.
No open-market insider buys or sells in the last 90 days.
No trades to chart yet.
SEC filings of any kind. 50 means a normal week.
Institutions added 14.0% to their holdings. 48 bought, 27 sold. 5 quarters of net buying in a row.
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
4,570 shares at $16.90 avg ($16.71 to $17.90) · $77K
9,447 shares at $16.91 avg ($16.71 to $17.90) · $160K
620 shares at $17.90 · $11K
568 shares at $17.90 · $10K
623 shares at $17.90 · $11K
658 shares at $17.90 · $12K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page